Back to top

BioMarin reports Q2 non-GAAP EPS $1.20, consensus 95c

Reports Q2 revenue $990M, consensus $932.04M. “This quarter, we executed strongly across our portfolio while rapidly integrating Amicus into BioMar...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BioMarin Pharmaceutical Inc. (BMRN)